ConductScience.org, home

Paper34200522

Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update.

Stasi C and 3 others. J Clin Med, 2021. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update. Papers, record 34200522. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34200522

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update.
PubMed
Journal
J Clin Med
PubMed
Year
2021
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.44
iCite
Revised in PubMed
2024-08-12
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Stasi CCristinahttps://orcid.org/0000-0002-9146-9968
2Tiengo GGiacomo
3Sadalla SSinanhttps://orcid.org/0000-0001-5336-317X
4Zignego ALAnna Linda

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References51

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128516869
Recommendations for infectious disease screening in migrants to Western Europe with inflammatory arthropathies before starting biologic agents. Results from a multidisciplinary task force of four European societies (SIR, SER, SIMET, SEMTSI) facing the largest impact of the flow of migrants today.
Clin Exp Rheumatol2017https://conductscience.org/library/papers/28516869PubMed
230932440Occult HBV infection may negatively impact on drug survival in patients with rheumatoid arthritis on treatment with a first biologic drug. An appraisal from the Biologic Apulian Registry (BIOPURE).Reumatismo2019https://conductscience.org/library/papers/30932440PubMed
333810942The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma.Eur J Intern Med2021https://conductscience.org/library/papers/33810942PubMed
425447850American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.Gastroenterology2015https://conductscience.org/library/papers/25447850PubMed
528140087Rituximab: Mechanism of action and resistance.Semin Oncol2002https://conductscience.org/library/papers/28140087PubMed
618715666Statements from the Taormina expert meeting on occult hepatitis B virus infection.J Hepatol2008https://conductscience.org/library/papers/18715666PubMed
729720221Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study.Arthritis Res Ther2018https://conductscience.org/library/papers/29720221PubMed
828160426Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.Int J Rheum Dis2017https://conductscience.org/library/papers/28160426PubMed
928011918Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Biologics Treatment.J Infect Dis2017https://conductscience.org/library/papers/28011918PubMed
1029256314Hepatitis B virus reactivation in patients with rheumatoid arthritis: A single-center study.Mod Rheumatol2018https://conductscience.org/library/papers/29256314PubMed
1129405329Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.Hepatology2018https://conductscience.org/library/papers/29405329PubMed
1226879359Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.J Rheumatol2016https://conductscience.org/library/papers/26879359PubMed
1329611409Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience.Yonsei Med J2018https://conductscience.org/library/papers/29611409PubMed
1428320050Practice Pattern of Hepatitis B Testing in Rheumatoid Arthritis Patients: A Cross-National Comparison Between the US and Taiwan.Arthritis Care Res (Hoboken)2018https://conductscience.org/library/papers/28320050PubMed
1529223453HBV reactivation in rheumatic diseases patients under therapy: A meta-analysis.Microb Pathog2018https://conductscience.org/library/papers/29223453PubMed
1633161563Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors.Arch Pharm Res2020https://conductscience.org/library/papers/33161563PubMed
1728529116Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis.Joint Bone Spine2017https://conductscience.org/library/papers/28529116PubMed
1831550363
Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy.
J Infect Dis2020https://conductscience.org/library/papers/31550363PubMed
1932051458Moderate Risk of Hepatitis B Virus Reactivation in HBsAg-/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis.Sci Rep2020https://conductscience.org/library/papers/32051458PubMed
2031779676
Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital.
Arthritis Res Ther2019https://conductscience.org/library/papers/31779676PubMed

See all 51 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn Papers
39155780Hepatitis B virus infection, infertility, and assisted reproduction.J Zhejiang Univ Sci B2024https://conductscience.org/library/papers/39155780

Source PubMed

Download CSV of cited by

Genes12

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34200522

GET https://conductscience.org/api/papers/v1/34200522/references?page=2